36 results about "AIM antigen" patented technology

The present invention is directed to novel artificial T helper cell epitopes (Th epitopes) designed to provide optimum immunogenicity when used in peptide immunogens comprising B cell epitopes or peptide haptens, a target antigenic site of a target antigen for eliciting antibodies thereto. The artificial Th epitopes are covalently linked to the target antigenic site and optionally an immunostimulatory sequence to provide effective and safe peptide immunogens.

The present invention relates to method of amplifying a population of antigen-specific memory CD4+ T cells using artificial presenting cells expressing HLA class II molecules. In particular, the present invention relates to a method of amplifying a population of antigen-specific memory CD4+ T cells comprising the steps of i) providing a population of artificial antigen presenting cells consisting host cells that are genetically modified to stably express at least one MHC class II molecule along with at least one accessory molecule ii) loading the population of artificial antigen presenting cells of step i) with an amount of at least one antigen of interest and iii) coculturing the suitable population of a T cells with the population of artificial antigen presenting cells of step ii).

The invention relates to the technical field of immunity, in particular to a cBIN1 antibody and application thereof. Three CDR regions of a heavy chain of the cBIN1 antibody provided by the invention respectively have amino acid sequences as shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3; and three CDR regions of a light chain respectively have amino acid sequences as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6. The antibody has good binding capacity with an antigen, and accurate detection of a target antigen can be realized by using the antibody to prepare a reagent.

One aspect of the present disclosure relates to an immunochromatographic detection method for a target antigen in a biological sample, comprising the step of joining a linker having a first antibody and a quantum dot bead having a second antibody, with respect to the target antigen. By using the quantum dot beads and the linker, the method can successfully amplify detection strength and significantly increase detection sensitivity through a simple process without causing a loss of antigens participating in detection when using only quantum dot beads. Furthermore, the present disclosure can significantly amplify detection strength without an additional washing step, thus enabling excellent detection and identification of a physiological substance in a biological sample, even in an actual product, and can be used to provide a product with a competitive price.

A binary vector and the provision of expression of a target antigen-dependent regulatory cytokine using the synNotch technology, so as to partially release the cytokine to enhance the function of T cell and reduce the non-specific toxic and side effect of the cytokine. A synthetic notch receptor is used to construct plasmid vectors to achieve local cytokine secretion. One plasmid vector uses a specific antibody as an extracellular domain for identifying a target antigen, a notch core comprises a transmembrane domain and a specific enzyme cutting site on a notch receptor, and transcription factor GAL4VP64 is used as an intracellular domain. When the target antigen is identified, the enzyme cutting site on the notch will be identified by a corresponding enzyme to hydrolyze and cut the intercellular transcription factor GAL4VP64. Another plasmid vector carries DNA identification/binding domain GAL4UAS of transcription factor GAL4 and correspondingly activates a minimal promoter of a target gene, and after being hydrolyzed and cut, GAL4VP64 will be bound to the binding domain to activate transcription of subsequent genes so as to express IL12 and secrete same out of the cell.

The invention relates to the technical field of immunization and particularly relates to an antibody cBIN1 and application thereof. Three CDR regions of a heavy chain of the antibody cBIN1 provided bythe invention separately have amino acid sequences represented by SEQ ID NO: 1, 2 and 3; and three CDR regions of a light chain of the antibody cBIN1 separately have amino acid sequences representedby SEQ ID NO: 4, 5 and 6. The antibody has good binding ability with an antigen, and reagents prepared from the antibody can achieve accurate detection on target antigens.

The invention provides a data processing method and related equipment, and the method comprises the steps: querying data stored in a database according to the input data of a client, determining an abnormal problem of the client, carrying out the corresponding operation according to the antibody information stored in the database, and avoiding the continuous impact on the client from the same abnormal data. The method comprises the following steps: monitoring target input data corresponding to a target client; when the target antigen data matched with the target input data is stored in the database, obtaining target antibody information corresponding to the target antigen data, wherein multiple pieces of antigen data including target antigen data and multiple pieces of antibody informationincluding target antibody information are stored in the database, the target antigen data are input data causing abnormality of the target client, and the target antibody information comprises a source, a protocol number, data content and strategy configuration of the target input data; and executing a corresponding operation based on the strategy configuration of the target antibody information.

The invention discloses a label-free ratio fluorescence type antigen detection method. The method comprises the following steps: designing a single-stranded DNA which comprises a recognition DNA sequence for CRISPR and an aptamer of a target antigen, and constructing a component A by spacing the recognition DNA sequence and the aptamer through a plurality of continuous T basic groups; by taking a target antigen as a target, modifying an antibody of the target antigen on a 96-well plate to construct a component B; connecting the surface-carboxylated silicon dioxide microspheres with a DNA chain of which the tail end is modified with amino groups, and complementarily pairing auxiliary DNA with DNA with amino groups to form double chains, so as to construct a component C; adding the component A, the component B, the component C, copper ions, ascorbic acid, DAPI dye and exonuclease III into an object to be detected; and detecting red fluorescence and blue fluorescence of an object to be detected, and detecting the target antigen by a ratio fluorescence method. According to the ratio fluorescence method, the intensities of two kinds of fluorescence are compared to serve as signal parameters, the accuracy is higher, the sensitivity is higher, and the selectivity is better; and moreover, the sensitivity is improved, the defect that a traditional method needs to label an antibody is overcome, and the detection cost is saved.

The invention provides a cleaning-free universal ELISA fluorescence immunoassay probe as well as a preparation method and application thereof. The probe is characterized in that through an HBTU/DIEA coupling reaction, carboxyphenylboronic acid is modified onto g-C3N4, after ultrasonic exfoliation, a weak-fluorescence boric acid modified graphite phase carbon nitride nanosheet (BCNNS) can be obtained; an antibody (Ab) is labeled on the BCNNS to obtain a strong-fluorescence Ab-BCNNS composite material (ON), the fluorescence of the Ab-BCNNS composite material is quenched (OFF) along with additionof a target antigen, and the specific detection of the target antigen can be realized based on the ON-OFF phenomenon. And moreover, by changing the labeled antibody in the Ab-BCNNS, the selective detection of different target antigens can be realized.

The invention relates to the technical field of immunity, and particularly relates to a cBIN1 antibody and application thereof. Three CDR regions of a heavy chain of the cBIN1 antibody provided by the invention respectively have amino acid sequences shown as SEQ ID NO: 1, 2 and 3; and three CDR regions of a light chain respectively have amino acid sequences shown as SEQ ID NO: 4, 5 and 6. The antibody has good binding capability with an antigen; a reagent prepared from the antibody can realize the accurate detection on a target antigen.

The embodiment of the invention discloses a recombinant hansenula polymorpha cell disruption buffer solution for expressing a hand-foot-and-mouth disease vaccine antigen as well as a preparation method and application of the recombinant hansenula polymorpha cell disruption buffer solution. The cell disruption buffer solution is prepared from the following components: 1.00 g/L to 100.00 g/L of tromethamine, 10.00 g/L to 100.00 g/L of medicinal sodium chloride and 1.00 g/L to 100.00 g/L of glycerinum. By implementing the method disclosed by the invention, the breakage rate, the target protein content and the target antigen content of the recombinant hansenula polymorpha cell breakage product can be obviously improved.

The invention discloses a kit for quantitatively detecting the content of pregnancy-related protein A. The kit comprises a kit body, a sealing cover, a protective cover and a reagent, wherein a solidphase carrier hole, a sample hole, a detection antibody hole, a fluorescein hole, a washing hole and a reading hole are sequentially formed in the kit body; the kit contains all reagent components required for completing immunodetection; the end part of the solid phase carrier loaded in the kit is coated with a capture antibody, and the solid phase carrier is immersed into each hole in the kit sothat the combination of a target antigen in a detected sample and subsequent detection steps can be completed, and the manufacturing and maintenance costs are greatly reduced; the kit is high in detection result accuracy, good in linear relation and high in specificity, and reliable clinical reference value can be provided for early screening of Down's syndrome and early prediction of atherosclerotic plaque rupture.

The invention relates to a chimeric antigen receptor (CAR) and application thereof. The invention provides an ROR1 specific chimeric antigen receptor which comprises a signal peptide, an anti-human ROR1scFv, a hinge region, a transmembrane region, a 4-1BB intracellular domain and a CD3 zeta intracellular domain, the anti-human ROR1scFv can be combined with a target antigen in a high affinity mode, and off-target benefits are prevented; furthermore, an Fc fragment is introduced into the chimeric antigen receptor, so that the tumor killing effect can be improved, immune factor storm can be prevented, the safety and effectiveness of treatment can be improved, and a new scheme is provided for development of related medicines and tumor immunotherapy.